18528 Background: Erythropoietin [Epo] is widely used in the management of Chemotherapy-Induced Anemia [CIA] with reported response rates of 70% in the setting of clinical trials. To evaluate overall response rates and tumor specific response rates a retrospective study was performed. Methods: Chart reviews of 109 consecutive patients with chemotherapy-induced anemia were conducted from 2001–2004. Inclusion criteria were: age > 18 yrs, solid or non-myeloid hematological malignancy, receiving concurrent chemotherapy. Patients who received at least one dose of epo were also included, under the intention-to-treat principle. Hb, HCT and MCV during the course of chemotherapy and epo treatment were also collected. Transfusion requirements were also noted. Rise of 1gm Hb after receiving at least 8 weeks of epo was considered as evidence of responsiveness. Epoetin alpha was administered as 40,000 units weekly or darbepoietin at 200mcg q2 weeks and appropriate dose adjustments were made depending on responses. A PRBC transfusion after Day 29 was considered to be evidence of non-responsiveness. Results: Of 109 patients, 108 were considered eligible to be studied. The table shows the distribution of patients according to cancer type. Among the patients who received epo for 8 weeks, the epo response rate was 46%. 21 patients required transfusions after Day 29. Conclusions: Our data suggests that the community response rates to erythropoietin are lower than that reported in the literature. Tumor specific response rates were not statistically significantly (p > 0.05), although this may reflect the small number of patients in the study. A multivariate analysis is being performed to determine if there are predictive factors for response. [Table: see text] [Table: see text]